Clinical Trial Update: Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) [Phase 1]

View source ↗

Summary

Phase 1 safety study of IPI-504 in patients with gastrointestinal stromal tumors and soft tissue sarcomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors
• Soft Tissue Sarcomas

Drugs mentioned

• IPI-504 (retaspimycin hydrochloride)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas | Phase 1 | Status: COMPLETED